Loading
A phase 2 trial of irinotecan-ChemoSeed implementation into the resection cavity after surgical resection of GBM in glioma & glioblastoma, run by CRISM Therapeutics LTD, now recruiting.
Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma is a phase 2 interventional study registered as NCT07356973 by CRISM Therapeutics LTD, with 147 participants planned, started 2026-08-20 and due to reach its primary completion in 2029-05. Interventions recorded: irinotecan-ChemoSeed implementation into the resection cavity after surgical resection of GBM.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Topoisomerase-I inhibitors (and ADC payloads), Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/